GLP1R and obesity due to melanocortin 4 receptor deficiency: This is of potential clinical relevance, as further defining the commonalities and differences between GLP-1R agonists and bariatric surgery in terms of their central mechanism of action may not only help bridge the gap between the pharmacological and surgical treatments for obesity but may also provide a neural basis for their combined use when each individually fail [174, 175].